
MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients
How to Cite
OrthoEvidence. MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients. ACE Report. 2013;2(7):612. Available from: https://myorthoevidene.com/AceReport/Report/5098
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was eff...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.